Showing results (201-210 of 330) with videos related to
Sort By:
Pageof 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2012
A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifenStephen K Chia, Vivien H Bramwell, Dongsheng Tu, et al.Clinical Transplantation|January 10, 2021
African Americans' discussions about living-donor kidney transplants with family or friends: Who, what, and why not?Nicole DePasquale, Matthew J Ellis, Debra L Sudan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2016
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)Maura N Dickler, William T Barry, Constance T Cirrincione, et al.International Journal of Radiation Oncology, Biology, Physics|July 12, 2024
Increased Synthetic Cytotoxicity of Combinatorial Chemoradiation Therapy in Homologous Recombination Deficient TumorsJennifer Ma, Rachna Shah, Andrew C Bell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trialVered Stearns, Judith-Anne W Chapman, Cynthia X Ma, et al.Cancer|May 3, 2017
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27Allan Lipton, Judith-Anne W Chapman, Kim Leitzel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2010
A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancerTorsten O Nielsen, Joel S Parker, Samuel Leung, et al.Proceedings of the National Academy of Sciences of the United States of America|December 1, 2018
DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancerRyoichi Matsunuma, Doug W Chan, Beom-Jun Kim, et al.Proceedings of the National Academy of Sciences of the United States of America|July 2, 2009
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancerCarrie R Graveel, Jack D DeGroot, Yanli Su, et al.Nature Genetics|September 28, 2023
Molecular classification of hormone receptor-positive HER2-negative breast cancerXi Jin, Yi-Fan Zhou, Ding Ma, et al.Pageof 33